Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-04-30 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,071,977; 10,149,829; 10,376,487; 9,060,995; 9,539,234; 9,549,913; 9,730,910; 9,855,241; RE46,284; RE46,604 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-04-30 | 1 | of Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… V. THE PATENTS-IN-SUIT (U.S. PATENT NOS. RE46,604; 9,060,995; 9,539,234; 9,549,913;… U.S. Patent No. 9,060,995 29. Vanda is the owner… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and Case 1:18-cv-00651…#: 2 9,855,241 (“the ’241 patent”) (collectively “the Asserted Patents”), which, in relevant part, | External link to document | |
| 2019-12-03 | 113 | Notice of Service | U.S. Patent No. 10,071,977; (2) Defendants' Amended Invalidity Contentions Regarding U.S. Patent No. 10,149,829…30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-12-10 | 114 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent No. 10,071,977 to Teva; and (2) Vanda's Supplemental Infringement…Infringement Contentions for U.S. Patent No. 10,071,977 to MSN filed by Vanda Pharmaceuticals Inc..(Fahnestock…30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-12-23 | 117 | Notice of Service | Invalidity Contentions Concerning U.S. Patent No. 10,071,977 2) Defendants Second Amended Invalidity …Invalidity Contentions Regarding U.S. Patent No. 10,149,829 3) Defendants Third Amended Invalidity Contentions …30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-12-12 | 336 | Opinion | claim 3 of U.S. Patent No. RE46,604 (the RE604 patent), claim 14 of U.S. Patent No 10,149,829 (the #829 patent… patent), claim 4 of U.S. Patent No. 9,730,910 (the #910 patent), and claim 5 of U.S. Patent No. 10,376,487…The Asserted Patents 1. The RE604 Patent 58) The RE604 patent, titled "…3 of the RE604 patent and that claim 3 of the RE604 patent, claim 4 of the #829 patent, claim 14 of the… #487 patent). Defendants have stipulated to infringement of claim 5 of the #487 patent. They | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
